» Articles » PMID: 35237513

A Novel Nomogram Model to Identify Candidates and Predict the Possibility of Benefit From Primary Tumor Resection Among Female Patients With Metastatic Infiltrating Duct Carcinoma of the Breast: A Large Cohort Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Mar 3
PMID 35237513
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The impact of primary site surgery on survival remains controversial in female patients with stage IV breast cancer. The purpose of this study was to investigate the role of primary tumor surgery in patients with stage IV breast cancer and concurrently develop a nomogram to identify which patients will benefit from surgery.

Methods: We retrospectively searched the SEER database for female patients newly diagnosed with stage IV breast infiltrating duct carcinoma (BIDC) between 2010 and 2015 and then divided them into surgery and non-surgery groups. The propensity score matching (PSM) method was implemented to eliminate the bias, and Kaplan-Meier survival analysis was generated to compare the overall survival (OS) and cancer-specific survival (CSS) between the two groups. After PSM, Cox regression analyses were performed to determine the independent protective value of primary tumor surgery, while logistic regression analyses were utilized to uncover significant predictors of surgical benefit and establish a screening nomogram for female patients with stage IV BIDC. Nomogram performance was evaluated by calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).

Result: 5,475 patients with stage IV BIDC were included in this study, and 2,375 patients (43.38%) received primary tumor surgery. After PSM, the median CSS was 53 months (95% CI: 46.84-59.16) in the surgery group compared with only 33 months (95% CI: 30.05-35.95) in the non-surgery group. We further found that primary tumor surgery was an independent protective factor for patients with stage IV BIDC. The independent factors affecting the benefit of locoregional surgery in patients with stage IV BIDC included histological grade, T stage, molecular subtype, lung metastasis, liver metastasis, brain metastasis, and marital status. The AUC of the nomogram was 0.785 in the training set and 0.761 in the testing set. The calibration curves and DCA confirmed that the nomogram could precisely predict the possibility of benefit from primary tumor resection.

Conclusion: Our study suggested that primary tumor surgery improved the prognosis of female patients with stage IV BIDC and developed a nomogram to quantify the probability of surgical benefit to help identify surgical candidates clinically.

Citing Articles

Machine learning-based prognostic modeling and surgical value analysis of de novo metastatic invasive ductal carcinoma of the breast.

Wei C, Li H, Li J, Liu Y, Zeng J, Tian Q Updates Surg. 2025; .

PMID: 39812957 DOI: 10.1007/s13304-025-02066-8.


Surgical resection of primary tumors improves survival in patients with lung metastases: a population-based SEER analysis.

Liu T, Lv X, Yang L, Yang Z, Jia C, Chen H Transl Cancer Res. 2023; 12(5):1128-1144.

PMID: 37304535 PMC: 10248564. DOI: 10.21037/tcr-22-2459.


Development of a predictive model to identify patients most likely to benefit from surgery in metastatic breast cancer.

Bai J, Li Z, Guo J, Gao F, Zhou H, Zhao W Sci Rep. 2023; 13(1):3845.

PMID: 36890157 PMC: 9995350. DOI: 10.1038/s41598-023-30793-8.

References
1.
Balachandran V, Gonen M, Smith J, DeMatteo R . Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015; 16(4):e173-80. PMC: 4465353. DOI: 10.1016/S1470-2045(14)71116-7. View

2.
Khan S, Stewart A, Morrow M . Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery. 2002; 132(4):620-6; discussion 626-7. DOI: 10.1067/msy.2002.127544. View

3.
Thomas A, Khan S, Chrischilles E, Schroeder M . Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011. JAMA Surg. 2015; 151(5):424-31. PMC: 5844269. DOI: 10.1001/jamasurg.2015.4539. View

4.
Yu Y, Hong H, Wang Y, Fu T, Chen Y, Zhao J . Clinical Evidence for Locoregional Surgery of the Primary Tumor in Patients with De Novo Stage IV Breast Cancer. Ann Surg Oncol. 2021; 28(9):5059-5070. DOI: 10.1245/s10434-021-09650-3. View

5.
Smid M, Wang Y, Zhang Y, Sieuwerts A, Yu J, Klijn J . Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008; 68(9):3108-14. DOI: 10.1158/0008-5472.CAN-07-5644. View